Introduction Cellcept, with mycophenolate mofetil (MMF) as active substance, was granted a marketing authorisation on 14 February 1996. On 16 July 2001, paediatric transplantations were included in the therapeutic indication. The current therapeutic indication is: Cellcept is indicated in combination with cyclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patie...

A 49-year-old man presented after a ruptured globe repair of his left eye status post a bungee cord injury with decreased vision in his right eye six weeks after the trauma occurred. Visual acuities were 20/40 in the right eye and no light perception in the left eye. Intraocular pressures were 27 and 5, respectively. Slit lamp examination of the right eye revealed 1+ conjunctival injection, fin...

IntroductionThere have been only modest improvements in the 90% survival rate at one year after heart transplantation since 1990s. This is largely due to antibody mediated rejection, cardiac allograft vasculopathy, malignancy, and immunosuppressive complications such as infection. Here, we present a case of disseminated Yersinia four years orthotopic transplant.Case ReportA 68 old gentleman wit...

We compared steady-state pharmacokinetics of mycophenolate mofetil (MMF) - Myfenax(®) (Teva) and CellCept(®) (Roche) - in stable kidney transplant recipients (KTRs). This was an international, multi-centre, randomized, open-label, two-treatment, two-sequence crossover study with a 3-month follow-up. We included KTRs at least 12 months post-transplantation with stable renal graft function for at...

BACKGROUND Therapeutic drug monitoring for mycophenolic acid (MPA) is increasingly being advocated. The present therapeutic range relates to the 12-hour area under the serum concentration time profile (AUC).However, this is a cumbersome, tedious, cost restricting procedure. Is it possible to reduce this sampling period? AIM To compare the AUC from a reduced sampling strategy with the full 12-...

OBJECTIVE To compare the clinical efficacy and bioequivalence of generic immunosuppressive drugs in patients with solid organ transplants. DESIGN Systematic review and meta-analysis of all studies comparing generic with innovator immunosuppressive drugs. DATA SOURCES Medline and Embase from 1980 to September 2014. REVIEW METHODS A literature search was performed for all studies comparing ...